Let-7b-5p sensitizes breast cancer cells to doxorubicin through Aurora Kinase B

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• MicroRNAs (miRNAs) are key regulators of gene expression.
• Aberrant miRNA expression is implicated in breast cancer (BC) progression and drug resistance.
• Doxorubicin (Dox) resistance is a major challenge in BC treatment.

Purpose of the Study:

• To investigate the role of let-7b-5p in Doxorubicin resistance in breast cancer.
• To explore the relationship between let-7b-5p, Aurora Kinase B (AURKB), and Doxorubicin resistance.
• To determine the therapeutic potential of targeting the let-7b-5p/AURKB axis.

Main Methods:

• Bioinformatic analysis of miRNA expression and gene correlation using public datasets (GEO).
• Quantitative PCR (qPCR) to validate miRNA and gene expression in BC tissues.
• Functional studies in breast cancer cell lines (MCF-10A, MCF-7, MDA-MB-231) to assess let-7b-5p effects on cell viability and Dox sensitivity via AURKB.

Main Results:

• let-7b-5p was significantly downregulated in breast cancer tissues.
• AURKB was identified as a key target gene negatively correlated with let-7b-5p and associated with Doxorubicin resistance.
• let-7b-5p restoration inhibited cancer cell growth and sensitized cells to Doxorubicin by downregulating AURKB.

Conclusions:

• The let-7b-5p/AURKB axis plays a critical role in breast cancer progression.
• Disruption of this axis contributes to Doxorubicin resistance.
• Targeting the let-7b-5p/AURKB pathway presents a potential strategy to overcome Doxorubicin resistance in breast cancer.